Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

T1INTERNATIONAL USA

Filed by T1INTERNATIONAL USA.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 15, 2026
Income
Not reported
Expenses
Not reported
Filing UUID
4ee3d969-43ac-4096-8078-a0acb64ba016
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to the following bills: oAffordable Drug Manufacturing Act (no bill number yet) - To establish an Office of Drug Manufacturing within HHS and for them to manufacture generic drugs that the federal government has licensed. oS.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. oH.R.3269/S.2276: ETHIC Act - would curb the practice of patent thicketing, bringing competition to the domestic biosimilars market and increasing access to lower cost treatments and cures.

Literal federal measure citations: S.2276

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.